Log in
menu
RESOURCES
Guides
API
FAQ
Recent Changes
Report Issue
ABOUT
About Wikirate
Community
Data
Impact
All Categories
--------------
Companies
Metrics
Sources
Topics
Data Sets
Projects
Research Groups
Company Groups
search
arrow_back_ios
Companies
Metrics
Sources
Topics
Data Sets
Projects
Research Groups
Company Groups
arrow_forward_ios
Home
Answers
US Securities and Exchange Commission+Research and Development Expense+Regeneron Pharmaceuticals+2022
attribution
history
edit
build
Question:
What is the company's aggregated costs regarding research and development?
Answer:
3.59B
USD
WikiRate ID:
16243655
Metric Designer:
US Securities and Exchange Commission
Metric Title:
Research and Development Expense
Company:
Regeneron Pharmaceuticals
Year:
2022
Status:
Unverified - Added by Steward
Details
Years
15
calculations
0
Contributions
updated
5 months ago by
Wikirate International e.V.
Review
Flag!
Source
history
edit
build
REGENERON PHARMACEUTICALS, INC.'s Annual Form 10-K report 2022
www.sec.gov
Answers
30
more_horiz
close_fullscreen
Original
file_download
Download
open_in_full
Open in full page
close_fullscreen
Open in new window
fullscreen
Open in modal
edit
Edit
build
Advanced
Comments